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Abstract
Simian foamy viruses (SFVs) belong to a genetically and antigenically diverse class of retroviruses that naturally infect a wide range of
nonhuman primates (NHPs) and can also be transmitted to humans occupationally exposed to NHPs. Current serologic detection of SFV infection
requires separate Western blot (WB) testing by using two different SFV antigens [SFVAGM (African green monkey) and SFVCPZ (chimpanzee)].
However, this method is labor intensive and validation is limited to only small numbers of NHPs. To facilitate serologic SFV testing, we developed
a WB assay that combines antigens from both SFVAGM and SFVCPZ. The combined-antigen WB (CA-WB) assay was validated with 145 serum
samples from 129 NHPs (32 African and Asian species) and 16 humans, all with known SFV infection status determined by PCR. Concordant
CA-WB results were obtained for all 145 PCR-positive or -negative primate and human specimens, giving the assay a 100% sensitivity and
specificity. In addition, no reactivity was observed in sera from persons positive for human immunodeficiency virus or human T cell lymphotropic
virus (HIV/HTLV) (n  25) or HIV/HTLV-negative U.S. blood donors (n  100). Using the CA-WB assay, we screened 360 sera from 43 Old
World primate species and found an SFV prevalence of about 68% in both African and Asian primates. We also isolated SFV from the blood of
four seropositive primates (Allenopithecus nigroviridis, Trachypithecus franc¸oisi, Hylobates pileatus, and H. leucogenys) not previously known to
be infected with SFV. Phylogenetic analysis of integrase sequences from these isolates confirmed that all four SFVs represent new, distinct, and
highly divergent lineages. These results demonstrate the ability of the CA-WB assay to detect infection in a large number of NHP species, including
previously uncharacterized infections with divergent SFVs.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Foamy viruses (FVs), or Spumaviruses, are exogenous
retroviruses present in many healthy mammals, including
monkeys and apes (Meiering and Linial, 2001). Among
primates, FVs have been isolated from a variety of both Old
and New World primates (Meiering and Linial, 2001).
About 70–90% of captive-bred, adult nonhuman primates
(NHPs) are infected with simian FVs (SFVs) (Meiering and
Linial, 2001). However, this seroprevalence is based on
screening of only a small number of primate species mostly
representing animals used in biomedical research, such as
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rhesus macaques (MAC), chimpanzees (CPZ), orangutans
(PON), baboons (BAB), and African green monkeys
(AGM) (Meiering and Linial, 2001). While only limited
information is available on the presence of SFV in captive
NHPs, even less is known about the prevalence of SFV in
wild-caught animals.
The SFV genome is organized similar to other complex
simian retroviruses and consists of gag, polymerase (pol),
and envelope (env) genes flanked by long terminal repeats
(LTRs). In Western blot (WB) analysis, seroreactivity in
SFV-infected primates is consistently detected to the Gag
p68/71 precursor proteins and is thus considered to be a
diagnostic marker of infection (Hahn et al., 1994; Schweizer
et al., 1995). However, the Gag proteins from apes and
monkeys share only about 60% amino acid identity and are
only weakly cross-reactive in WB assays (Hahn et al., 1994;
Herchenroder et al., 1994). Thus, serologic WB testing for
SFV antibodies in monkeys and apes, as well as humans
exposed to these primates, requires the use of two tests—
one that contains antigen from an African green monkey
(SFVAGM) and the other containing antigen from a chim-
panzee (SFVCPZ), which would allow detection of antibod-
ies to both the Old World monkey or the ape SFV variants,
respectively (Schweizer et al., 1995). Other serologic meth-
ods such as immunoflouresence or radioimmunoprecipita-
tion have also been used for the detection of SFV antibodies
(Hahn et al., 1994; Khan et al., 1999). In addition to sero-
logic testing, PCR testing for SFV sequences in peripheral
blood lymphocytes (PBLs) by using generic integrase, pol,
and LTR primers has also been used to detect the presence
of SFV infection (Bieniasz et al., 1995; Broussard et al.,
1997; Schweizer and Neumann-Haefelin, 1995).
Previous studies examining the genetic variability of
SFVs suggested that these retroviruses have coevolved with
their natural hosts (Blewett et al., 2000; Broussard et al.,
1997; Heneine et al., 1998; Schweizer and Neumann-Haefe-
lin, 1995). Thus, SFV sequences from baboons, AGMs, and
mangabeys formed an African Old World monkey clade,
while SFV sequences from Asian macaques were in a sep-
arate lineage. Similarly, SFV sequences from the great apes
such as bonobos, chimpanzees, orangutans, and gorillas
formed another distinct clade.
While SFVs are known to endemically infect a large
number of NHPs, there is little evidence that humans are
naturally infected with FVs. Surveys of a large number of
humans from many different geographic locations and eth-
nic backgrounds have failed to show evidence of FV infec-
tion (Ali et al., 1996; Schweizer et al., 1995). Nonetheless,
more recent investigations evaluating cross-species trans-
mission of simian retroviruses to persons at risk for occu-
pational exposures to NHPs reported transmission of SFVs
to humans (Boneva et al., 2002; Brooks et al., 2002; He-
neine et al., 1998; Sandstrom et al., 2000; Schweizer et al.,
1995). To date, these studies have identified SFV infection
in 2–3% of persons with occupational exposures to NHPs
at research institutions or zoos. SFV in these primate work-
ers was shown by phylogenetic analysis to have originated
from baboons (n  4), AGMs (n  2), chimpanzees (n 
6), and macaques (n  1) (Brooks et al., 2002; Heneine et
al., 1998; Sandstrom et al., 2000; Schweizer et al., 1995,
1997). Similar to the natural host, SFV-infected humans are
apparently asymptomatic despite serologic evidence of a
long persistent infection. However, longitudinal follow-up of a
large number of infected persons may be necessary to fully
assess any clinical outcomes associated with SFV infection.
The presence of zoonotic SFV infections in humans has
increased the importance of defining the public health im-
plications of these infections. These studies require an ex-
panded surveillance to identify SFV-infected persons and
therefore will need improved diagnostic assays. These as-
says should be less laborious by not requiring multiple
testing with different SFV antigens, and they should be
validated on a wide range of SFV variants.
In this study, we have developed a WB assay that com-
bines antigens from SFVAGM and SFVCPZ into a single test.
The combined-antigen WB (CA-WB) assay was validated
with serum samples from primates representing 32 African
and Asian primate species and 16 humans with known SFV
infection. We also examined the seroprevalence of SFV in
a large number of captive-bred and wild-born African and
Asian NHP species. In addition, we report the isolation and
identification of SFVs from four primate species not previ-
ously known to be infected with SFV and show phyloge-
netic evidence that each represents a new, distinct lineage.
Results
Validation of the CA-WB assay
Concordant CA-WB test results were obtained with se-
rum samples from all 94 PCR-positive and 35 PCR-negative
primates representing 23 African and 9 Asian monkeys and
apes (Table 1). Seroreactivity to the combined SFVAGM and
SFVCPZ Gag doublet proteins ranged from weak to strong
positive for samples from the PCR-positive NHPs. Com-
pared to other NHPs, the weakest seropositive reactivity
was observed for sera from PCR-positive orangutans (Fig.
1). Concordant CA-WB results were also observed for all 11
PCR-positive and 5 PCR-negative human specimens. The
sensitivity, specificity, predictive value positive, and predic-
tive value negative measures of the CA-WB assay were
determined to be 100% for these specimens. None of the 25
serum samples from humans infected with human immuno-
deficiency virus type 1 or 2 (HIV-1 or -2) or human T cell
lymphotropic virus type 1 or 2 (HTLV-1 or -2) showed
cross-reactivity to the diagnostic SFV Gag proteins. Simi-
larly, negative CA-WB results were also seen with all 100
U.S. human blood donor sera.
Prevalence of antibodies to SFV in captive-bred and wild-
born primates
With the observed high sensitivity and specificity of the
CA-WB assay, we proceeded to determine the seropreva-
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lence of SFVs in a large number of captive-bred and wild-
born NHPs. Of the 286 captive-bred NHPs tested, 211
(73.8%) were found to be seropositive, while 75 (26.2%)
were seronegative (Table 2). There was no significant dif-
ference between the SFV seroprevalence rates among cap-
tive-bred NHPs from Africa (73.5%) and Asia (74.2%).
These results show that SFV is present in a variety of
NHPs, including those not typically used in biomedical
research, such as langurs, gibbons, Allen’s swamp mon-
keys, colobus monkeys, many guenons, and Barbary ma-
caques. However, many serum samples from captive-bred
red-eared guenons (n  2), black-crested mangabeys (n 
3), Angolan colobus monkeys (n  4), drills (n  11), and
siamangs (n  4) were found to be seronegative (Table 2a
and 2b).
Although there was a broad range of seropositivity in
both the captive-bred and the wild-born primates, the over-
all SFV seroprevalence was lower in animals born in the
wild (73.8 vs 44.6%, respectively) (Table 3). In addition,
when seroprevalence rates were compared directly between
identical species of wild-born and captive-bred monkeys, a
higher rate was observed in captive-bred guenons (2/7 or
28.6%) than in similar wild-born guenons (0/20). However,
a lower seroprevalence was not seen in all captive-bred
NHPs. For example, the prevalence of SFV antibodies
among both captive-bred and wild-born red-capped manga-
beys was very similar (62.5 and 61.5%, respectively). When
the serology results for all 43 species of captive-bred and
wild-born Old World primates are combined, there is an
overall SFV seroprevalence of about 68% in both Asian and
African NHPs.
CA-WB testing of one specimen from a wild-born
Bornean orangutan showed indeterminate results (1/20 or
5.0%) (data not shown). However, this sample was found to
be seropositive upon repeat WB testing using an antigen
derived from an orangutan (SFVPON) (data not shown).
These results may indicate a reduced cross-reactivity of
SFVPON antibodies to the SFVAGM and SFVCPZ antigens
likely due to a high degree of antigenic variability. DNA
specimens were not available on the Bornean orangutans
for PCR analysis. However, one serum sample from a
PCR- and CA-WB-negative Sumatran orangutan remained
seronegative upon retesting with the autologous SFVPON
antigen.
Table 1
Validation of the combined simian foamy virus antigen Western blot assay (CA-WB) using sera from 32 nonhuman primate species (129 different
animals) with known infection status determined by PCR analysis
Genus Species Common name Number CA-WB/PCR CA-WB/PCR
Cercopithecus neglectus De Brazza’s monkey 3 3/3
lhoesti L’Hoest’s monkey 1 1/1
erythrotis Red-eared guenon 1 1/1
diana Diana monkey 1 1/1
mitis albogularis Sykes’s monkey 3 3/3
Chlorocebus pygerythrus Vervet monkey 6 5/5 1/1
Mandrillus sphinx Mandrill 17 8/8 9/9
leucophaeus Drill 7 1/1 6/6
Cercocebus atys Sooty mangabey 2 2/2
torquatus Red-capped mangabey 4 4/4
chrysogaster Golden-bellied mangabey 4 4/4
Lophocebus aterrimus Black-crested mangabey 4 4/4
albigena Gray-cheeked mangabey 3 3/3
Papio papio Guinea baboon 12 12/12
hamadryas Hamadryas baboon 1 1/1
cynocephalus Yellow baboon 1 1/1
anubis Olive baboon 5 5/5
Theropithecus gelada Gelada baboon 3 3/3
Macaca silenus Lion-tailed macaque 2 2/2
fuscata Japanese macaque 5 4/4 1/1
arctoides Stump-tailed macaque 4 4/4
sylvanus Barbary macaque 10 6/6 4/4
Colobus guereza Mantled guereza 5 5/5
Pygathrix nemaeus Red-shanked Douc langur 1 1/1
Pan troglodytes troglodytes Central African chimpanzee 3 3/3
troglodytes schweinfurthii East African chimpanzee 3 3/3
paniscus Bonobo 2 2/2
Gorilla gorilla Western lowland gorilla 6 6/6
Hylobates lar White-handed gibbon 2 2/2
leucogenys White-cheeked gibbon 2 2/2
Pongo pygmaeus Bornean orangutan 2 2/2
abelii Sumutran orangutan 4 3/3 1/1
Totals 129 94/94 (100%) 35/35 (100%)
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Isolation of SFVs and phylogenetic analysis of novel
integrase sequences
From the serosurvey of captive-bred NHPs, we identified
several primate genera not previously known to be SFV-
infected. Thus, to confirm the observed seropositivity, PCR
amplification of integrase sequences with generic primers
was attempted on PBL DNA lysates available from sero-
positive Allen’s swamp monkeys (Allenopithecus nigroviri-
dis), two species of langurs (Pygathrix nemaeus and Tra-
chypithecus franc¸oisi), and two gibbon species (Hylobates
pileatus and H. leucogenys). All 18 samples tested PCR-
negative (Table 4), although the quality of each PBL DNA
sample was confirmed by PCR amplification of -actin
sequences (data not shown). Cryopreserved PBL samples
were available from one each of the Allen’s swamp mon-
keys, Franc¸ois’ langurs, and gibbons for virus isolation. The
presence of SFV in the cocultures was confirmed by the
presence of typical FV cytopathic effect, the detection of
reverse transcriptase (RT) activity in the culture superna-
tants, and PCR amplification of SFV integrase sequences
from the cultured cells. The positive PCR results found in
cultured cells but not in uncultured PBLs reflect the reduced
sensitivity of the generic PCR assay, which is likely due to
sequence variability in the primer regions and which can be
overcome in samples containing high copy numbers of SFV
DNA.
By the formation of four distinct lineages, phylogenetic
analysis confirmed that the integrase sequences obtained
from the cell-culture isolates are novel and highly divergent
from all available SFV sequences (Fig. 2). As expected, the
Hylobates sequences formed two closely related yet distinct
lineages nearest the integrase sequences from another ape,
the chimpanzee. The Trachypithecus integrase sequence
formed a separate lineage between the apes and Asian
macaques, while the Allenopithecus lineage clustered be-
tween the Cercocebus and Macaca sequences. Identical tree
topologies were also obtained with both the maximum like-
lihood and the minimum evolution methods, providing fur-
ther evidence of the genetic relationships of these unique
SFV lineages (data not shown). The nucleotide diversity
between the new lineages and known SFV integrase se-
quences ranged from 20 to 30%, with the highest percentage
divergence seen with the gibbon and langur SFVs.
To implement a nomenclature system that more easily
differentiates among unique SFVs, especially those ob-
tained from the same genus, we propose using a three-letter
code that consists of the first letter of the primate genus
from which the SFVs were isolated with the first two letters
of either the species or, if known, the subspecies name.
Thus, the isolates from A. nigroviridis, T. francoisi, H.
pileatus, and H. leukogenys are provisionally named
SFVANI, SFVTFR, SFVHPI, and SFVHLE, respectively. For
completion, the name or code given to the animal could then
be added to the three-letter primate designation. For
example, SFVANI isolated from a swamp monkey with the
animal identification code 598422 would be named
SFVANI598422. This system will require approval by viral
taxonomy specialty groups.
Discussion
Cross-species transmission of retroviruses from NHPs
has been linked to the origin of the HIV pandemic, with
HIV-1 and HIV-2 believed to be the result of zoonotic
transfer of simian immunodeficiency viruses (SIVs) from
chimpanzees and sooty mangabeys, respectively (Hahn et
al., 2000). Similarly, phylogenetic evidence suggests that
the HTLV-1 subtypes may have arisen from multiple intro-
ductions of the simian T cell lymphotropic virus type 1
(STLV-1) into ancient human populations (Slattery et al.,
1999). The renewed investigations of the spread and clinical
outcome of SFV infections among humans require the avail-
Fig. 1. Detection of antibodies to simian foamy virus (SFV) in representative nonhuman primates and in an occupationally exposed human by using the
combined antigen [SFVAGM (African green monkey) and SFVCPZ (chimpanzee)] Western blot assay. Lanes 1–5 are sera from African monkeys; lanes 6–8
are sera from Asian monkeys; lanes 9– 12 are sera from African and Asian apes; and lane 13 is from a human infected with SFV originating from a
chimpanzee. Seroreactivity was observed to the diagnostic Gag doublet protein (p68/71) in all specimens and to the Bet protein (p60) in the chimpanzee
specimens. The molecular weight protein marker sizes are indicated on the left.
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ability of improved serologic assays capable of detecting
SFV antibodies in a broad spectrum of Old World monkeys
and apes. Thus, we developed and validated a serologic
assay that combines two divergent antigens from SFVAGM
and SFVCPZ in a single test.
The 100% sensitivity and specificity observed among
samples from 32 primate species confirms the ability of this
assay to detect divergent SFVs. These data support the use
of the CA-WB assay in assessing risks of SFV transmission
to persons exposed to a wide variety of NHPs and in
determining the incidence and seroprevalence of SFV in-
fection in captive and feral NHPs. We also show an absence
of reactivity with human sera from persons infected with
HIV or HTLV, confirming a lack of cross-reactivity with
this assay. By requiring only a single test for SFV antibody
detection, the new CA-WB assay will facilitate the screen-
ing of larger populations.
Previous studies of the prevalence of SFV infection in
NHPs have been limited to small numbers and types of
animals housed at research centers, such as baboons, ma-
caques, chimpanzees, AGMs, and a few New World mon-
keys and prosimians (Blewett et al., 2000; Meiering and
Linial, 2001). However, exposures to a larger variety of
NHPs and their simian retroviruses may occur in persons
who work in zoological gardens and individuals who live in
close contact with monkeys, such as bush-meat hunters or
pet owners (Peeters et al., 2002). Nonetheless, little is
known about the prevalence of SFV infection in monkeys
and apes found in these settings.
Our study is the first to our knowledge to document such
an extensive distribution of SFV infection among NHP
species. Our finding of an overall 73.8% SFV seropreva-
lence rate in 35 of 40 species of captive-bred African and
Asian primates is significant and consistent with previous
estimates on the high prevalence rates (70%) of SFV
infections observed in small numbers of captive primates
used in biomedical research (Meiering and Linial, 2001). In
contrast, other simian retroviruses such as SIV and STLV
have both a lower distribution and a lower seroprevalance
(about 35%) among captive-bred and wild-born primates
(Fultz, 1994). These data suggest that persons exposed to
NHPs may be at higher risk for zoonotic infections with
SFV than with SIV or STLV, and the data may also help
explain the observed higher prevalence of SFV antibodies
(3%) in occupationally exposed persons than either SIV
(0.43%) or STLV (0%) (Heneine et al., 1998). These results
Table 2a
Seroprevalence of simian foamy virus in 29 species of captive-bred African monkeys and apes
Genus Species Common name Number
seropositivea
Rate (%)
Cercopithecus neglectus De Brazza’s monkey 4/5 80.0
cephus Mustached guenon 3/6 50.0
erythrotis Red-eared guenon 0/2 0.0
diana Diana monkey 2/2 100.0
albogularis Syke’s monkey 7/7 100.0
campbelli Campbell’s guenon 15/16 93.8
nictitans Spot-nosed guenon 1/4 25.0
solatus Sun-tailed guenon 1/1 100.0
pogonias Crowned guenon 1/1 100.0
pogonias X monab Hybrid 1/1 100.0
Chlorocebus pygerythrus Vervet monkey 2/2 100.0
tantalus Tantalus monkey 5/5 100.0
sabaeus African green monkey 4/8 50.0
Allenopithecus nigroviridis Allen’s swamp monkey 2/2 100.0
Miopithecus talapoin Dwarf guenon 13/15 86.6
Mandrillus sphinx Mandrill 11/13 84.6
leucophaeus Drill 0/11 0.0
Cercocebus atys Sooty mangabey 5/5 100.0
torquatus Red-capped mangabey 5/8 62.5
chrysogaster Golden-bellied mangabey 2/3 66.6
Lophocebus aterrimus Black-crested mangabey 0/3 0.0
albigena Gray-cheeked mangabey 4/4 100.0
Papio hamadryas Hamadryas baboon 4/4 100.0
anubis Olive baboon 4/4 100.0
Theropithecus gelada Gelada baboon 13/16 81.3
Macaca sylvanus Barbary macaque 3/3 100.0
Colobus guereza Mantled guereza 4/4 100.0
angolensis Angolan colobus 0/4 0.0
Pan troglodytes Common chimpanzee 13/15 86.6
Gorilla gorilla Western lowland gorilla 4/7 57.1
Totals 133/181 73.5
a Number of different animals.
b Crowned guenon and mona monkey hybrid; not included in species total.
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underscore the importance of work practices that prevent
exposure to these viruses and highlight the need for in-
creased surveillance and additional studies to define the
clinical outcomes and transmissibility of these infections.
We also found a generally lower prevalence of SFV
infection among wild-born primates (44.6%) than among
captive-bred animals (73.8%). These observed differences
in the prevalence of SFV among wild-born and captive-bred
NHPs may be attributed to the limited number of wild-born
NHPs tested or may reflect increased transmission in cap-
tive-bred animals. Interestingly, we also observed many
SFV-seronegative primates from both Africa and Asia in-
cluding captive-born red-eared guenons, black-crested
mangabeys, Angolan colobus monkeys, and siamangs, sug-
gesting that SFV in captive-bred NHPs may not be as
ubiquitous as previously thought. However, these negative
findings and the observed lower SFV seroprevalence in
wild-born primates may require confirmation by testing
larger numbers of animals. The observed negative WB re-
sults in these animals may not be due to a lower assay
sensitivity since SFV antibodies were detected in closely
related primate species.
While this study provides evidence that the CA-WB
assay is sensitive for the detection of antibodies to SFV
variants in 32 different NHP species, our findings also show
that the assay may not reliably detect antibodies to SFV in
sera from some orangutans. A similar weak cross-reactivity
of orangutan sera to SFVAGM and SFVCPZ has been ob-
served by others (Hahn et al., 1994). However, we show that
this limitation could be overcome by using the autologous
SFVPON antigen. The lack of cross-reactivity between
SFVPON-specific antibodies and the SFVAGM and SFVCPZ
Table 2b
Seroprevalence of simian foamy virus in 11 species of captive-bred Asian monkeys and apes
Genus Species Common name Number
seropositivea
Rate (%)
Macaca silenus Lion-tailed macaque 8/15 53.3
fuscata Japanese macaque 47/49 95.9
arctoides Stump-tailed macaque 2/2 100.0
mulatta Rhesus macaque 3/4 75.0
nigra Sulawesi-crested macaque 1/1 100.0
Pygathrix nemaeus Red-shanked Douc langur 4/5 80.0
Trachypithecus francoisi Franc¸ois’s langur 5/9 55.5
Hylobates pileatus Pileated gibbon 4/9 44.4
leucogenys White-cheeked gibbon 3/6 50.0
syndactylus Siamang 0/4 0.0
Pongo pygmaeus Bornean orangutan 1/1 100.0
Totals 78/105 74.2
Combined totalsb 211/286 73.8
a Number of different animals.
b Total for all captive-bred African and Asian primates in Tables 2a and 2b.
Table 3
Comparison of the seroprevalence of simian foamy virus (SFV) in eight species of wild-born and captive-bred primates
Genus Species Common name Number of
wild-born
seropositive (%)
Number of
captive-bred
seropositive (%)a
African
Cercopithecus mona Mona monkey 5/14 (35.7) NA
nictitans Spot-nosed guenon 0/14 1/4 (25)
erythrotis Red-eared guenon 0/5 0/2
pogonias Crowned guenon 0/1 1/1 (100)
preussi Preuss’s monkey 0/1 NA
sclateris Sclater’s guenon 0/6 NA
Cercocebus torquatus Red-capped mangabey 8/13 (61.5) 5/8 (62.5)
Asian
Pongo pygmaeus Bornean orangutan 20/20 (100.0)b 1/1 (100.0)
Totalsc 28/53 (52.8) 8/16 (50.0)
Combined totald 33/74 (44.6) 211/286 (73.8)
a NA, serum not available from this captive-bred species.
b Results are after repeat Western blot analysis of all orangutan sera with autologous SFVPON antigen (19 positive, 1 indeterminate with CA-WB testing).
PON, orangutan.
c Seroprevalence in primates with sera from the same wild-born or captive-bred species.
d Seroprevalence in all wild-born or captive-bred primates.
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antigens may be due to divergence in the highly conserved
epitopes in the SFVPON Gag proteins. For example, the
predicted SFVPON Gag sequence has only about 40–50%
identity to the SFVAGM and SFVCPZ Gag proteins, respec-
tively (McClure et al., 1994). In contrast, the Gag proteins
from SFVMAC, SFVAGM, and SFVCPZ share at least 64%
identity (Herchenroder et al., 1994). These results show that
testing for antibodies to SFVPON in orangutans or in persons
exposed to orangutans may require the inclusion of an
SFVPON antigen in the serologic screening assay.
The new SFVs identified in the current study represent
the first primate Spumaviruses described for Allen’s swamp
monkeys, gibbons, and langurs and demonstrate the broad
genetic diversity of Old World primate FVs. Phylogenetic
analysis of integrase sequences from the new SFV isolates
is consistent with a coevolution with their primate hosts as
previously suggested for other SFVs (Blewett et al., 2000;
Broussard et al., 1997; Schweizer and Neumann-Haefelin,
1995; Heneine et al., 1998). Old World monkeys and apes
are divided into four subfamilies, the Cercopithecines
(cheek pouch monkeys), Colobines (leaf-eating monkeys),
Hylobatids (lesser apes such as gibbons), and Hominids
(orangutans, gorillas, chimpanzees, and bonobos) (Groves,
2001). Thus, as expected, the Hylobate SFVs cluster near
the Hominid sequences; the Allenopithecus SFV sequence
forms a separate lineage with SFVs from other Cerco-
pithecines, and the SFV from a Colobine host, the Trachy-
pithecus, forms another unique lineage between the Cerco-
pithecine and Hominid subfamilies. The coevolution of
SFVs in Old World monkeys and apes combined with wide
distribution of distinct SFVs in the remaining primate tax-
onomic families, including New World monkeys and pro-
simians, suggests that ancestral SFVs were present in mam-
mals before primate speciation. Thus, if primate divergence
began at least 65 million years ago as previously estimated
(Martin, 1993), then SFVs may be the oldest known exog-
enous simian retroviruses.
Our study also shows that generic PCR assays may not
detect highly divergent SFVs. Thus, the CA-WB assay is a
better diagnostic tool, and the study results further support
the use of this method for the diagnosis and surveillance of
infection originating from divergent SFVs among both
NHPs and humans. Our ability to isolate SFVs from these
primates without detectable proviral sequences by PCR il-
lustrates the utility of virus isolation and confirms the ob-
served seropositivity in the CA-WB assay. Thus, our inabil-
ity to PCR amplify SFV sequences from the seropositive P.
nemaeus PBL DNA lysates may indicate that this species
may harbor yet another highly divergent SFV.
In conclusion, we have described a highly sensitive and
specific CA-WB assay for the detection of SFV antibodies
from both naturally infected primates and accidentally in-
fected humans. We have also shown that unlike other simian
retroviruses, SFVs have both a wide distribution and a high
seroprevalence among African and Asian NHPs. These re-
sults imply that persons who have frequent contact with
NHPs may be at increased risk for cross-species SFV in-
fection. The CA-WB assay should facilitate testing of larger
human populations for evidence of SFV infection.
Materials and methods
NHP specimens
A total of 489 serum or plasma specimens were collected
from 44 species of captive-bred African and Asian monkeys
and apes and 7 species of wild-born Nigerian monkeys (n 
54) and Bornean orangutans (n 20) as part of their initial or
annual physicals (Tables 1–3). Some of these specimens (n 
286) were archived serum samples available from NHPs re-
siding at zoological gardens or research centers in North Amer-
ica. Also, for selected NHPs (n 129), fresh EDTA or sodium
citrate treated blood specimens were obtained on an opportu-
nistic basis in accordance with the animal care use committees
at each institution. For PCR analysis, DNA or DNA lysates
were prepared from the PBLs as described in previous studies
(Broussard et al., 1997; Switzer et al., 1995). Primate taxo-
nomic nomenclature used herein was as described by Groves
(Groves, 2001).
Table 4
Novel simian foamy viruses isolated from peripheral blood lymphocytes (PBLs) of African and Asian primates with discordant combined antigen
Western blot (CA-WB) and integrase PCR results
Genus Species Common name CA-WBa PCRb Culturec
African
Allenopithecus nigroviridis Allen’s swamp monkey 2/2 0/2 1/1
Asian
Pygathrix nemaeus Red-shanked Douc langur 4/5 0/4 ND
Trachypithecus franc¸oisi Franc¸ois’ langur 5/9 0/5 1/1
Hylobates pileatus Pileated gibbon 4/9 0/4 1/1
leucogenys White-cheeked gibbon 3/6 0/3 1/1
Totals 18/31 0/18 4/4
a Number of CA-WB-positive sera of the total tested.
b PCR analysis was done only on primates with positive CA-WB results.
c Coculture of PBLs from representative primates with canine thymocytes (Cf2Th); PBLs were not available from all animals. ND, not done.
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SFV CA-WB assay
To avoid using two separate WB assays to test for SFV
antibodies, we combined antigens prepared individually
from SFVAGM- or SFVCPZ-infected canine thymocyte
cells (Cf2Th) into a single WB assay. Cf2Th cells were
maintained in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% heat-inactivated fetal bovine serum,
L-glutamine, penicillin–streptomycin, and fungizone
(Gibco-BRL, Gaithersburg, MD). At 30 – 40% confluency
the Cf2Th cells were infected with SFVAGM (ATCC
VR-218), SFVCPZ (ATCC VR-632), or SFVPON (a kind
gift of Dr. Paul B. Johnston). SFV-inoculated Cf2Th cells
were monitored for characteristic cytopathic effects
(CPE), and the cells were harvested by scraping when
40 –50% CPE was observed. Uninfected Cf2Th cells
were also maintained as negative virus antigen controls to
test for evidence of nonspecific cross-reactivity in some
samples.
Cell pellets were washed twice in PBS (pH 7.4) and then
lysed in detergent buffer containing 0.5 M Tris–Cl, pH 7.2,
10% SDS, and 1% glycerol. The lysates were boiled and
sonicated for 5 min and then homogenized by passing them
two or three times through a tuberculin syringe. The protein
concentration of the cell lysates was determined with the
Pierce protein kit (Rockford, IL). SFVAGM- and SFVCPZ-
infected cell lysates (150 g of each) were mixed and
denatured by boiling for 3 min in Laemmli buffer (Bio-Rad,
Valencia, CA). SFV-mixed or -uninfected Cf2Th cell ly-
sates were electrophoresed on 7.5% SDS–2D/prep Tris–
glycine polyacrylamide gels (Bio-Rad) at 70 V for 2 h and
then transferred to polyvinylidene difluoride membranes
(Bio-Rad). The membrane filters were blocked overnight at
4°C in blocking buffer [5% nonfat dry milk in Tris borate
Fig. 2. Unrooted phylogenetic tree of new simian foamy virus (SFV) integrase sequences (boxed text) from peripheral blood lymphocyte coculture isolates
from Hylobates pileatus (SFVHPI), H. leucogenys (SFVHLE), Trachypithecus franc¸oisi (SFVTFR), and Allenopithecus nigroviridis (SFVANI). Sequences used
for comparison were available at GenBank. Case 1 and SFVhumAGM, cases 2, 3, and 4, and the prototype HFV are from two SFVAGM, three SFVBAB,
and one SFV cpz-infected person(s), respectively (Achong et al., 1971; Heneine et al., 1998; Schweizer et al., 1997). SFVBAB, SFV3AGM and SFV3lk,
SFVSMM, SFVMAC and SFV1a and 1b and SFV2, SFVPYG, and SFV6CPZ and SFV7CPZ are integrase sequences from a baboon, African green monkeys, sooty
mangabey, macaques, bonobo, and chimpanzees, respectively. Distances were calculated by the Kimura two-parameter method, and phylogenetic relation-
ships were inferred by the neighbor-joining method. The significance of the branching order was determined by 1000 bootstrap replicates. The values on the
branches indicate frequencies of occurrence for 1000 trees and only values 60% or greater are shown. Branch lengths are drawn to scale. A similar tree
topology was obtained by the maximum likelihood and minimum evolution methods (data not shown). Percentage nucleotide divergence of the new SFVs
and their closest neighbors are shown.
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buffer (TBS) with 0.1% Tween 20] and washed once for 5
min in wash buffer (1% Tween 20 in TBS) at room tem-
perature. The proteins were incubated overnight at 4°C with
sera diluted 1:50 in blocking buffer. The membranes were
washed three times for 5–10 min each and incubated with a
1:6000 dilution of horseradish peroxidase conjugated pro-
tein A/G for 2 h at 4°C, followed by two 15-min washes.
Reactivity to protein bands was visualized by chemilumi-
nescence with the ECL kit (Amersham Pharmacia Biotech,
Piscataway, NJ). Seroreactivity to both Gag p68 and p71
precursor proteins was interpreted as seropositive. Speci-
mens without reactivity to either Gag protein were consid-
ered seronegative and those with reactivity to a single band
in the 68- to 74-kDa molecular weight range with an ab-
sence of similar reactivity to antigen from uninfected Cf2Th
cells were called seroindeterminate.
Validation of the SFV CA-WB assay
The CA-WB assay was validated with serum samples
from 32 African and Asian NHP species (n  129) (Table
1) and 16 humans [SFVBAB-infected (n  4), SFVCPZ-
infected (n  6), SFVAGM-infected (n  1), and SFV-
uninfected (n  5)]. The infection status of these NHPs and
human samples was determined by PCR analysis using
generic integrase primers as described below. Reactivity of
human sera from 25 persons infected with HIV-1/2 or
HTLV-1/2 and of HIV and HTLV-negative sera from 100
U.S. blood donors was also evaluated.
SFV seroprevalence in a large number of captive-bred
and wild-born NHPs
To define the prevalence of SFV infection in captive-
bred and wild-born NHPs and to assess the risks of occu-
pational exposures to SFVs in these settings, we used the
CA-WB assay to screen sera or plasma from 286 captive-
bred African and Asian NHPs (40 species) (Table 2) in 25
North American zoos and sera from 74 wild-born Nigerian
monkeys (7 species, n  54) and Bornean orangutans (1
species, n  20) (Table 3).
Isolation of SFV from NHP PBLs by coculture
Cocultivation of equal numbers of primate PBLs and
Cf2Th was done by using culture conditions reported pre-
viously (Heneine et al., 1998). Cultures were monitored
every 3–4 days for syncytial CPE typical of FV and for RT
activity using the Amp-RT assay as performed elsewhere
(Heneine et al., 1995). When at least 50% of each culture
showed CPE, the cells were trypsinized and DNA lysates
were prepared as described above. Isolates were confirmed
as SFVs by PCR and sequence analysis using generic inte-
grase primers as described below.
PCR and DNA sequence analysis
Amplification of SFV proviral sequences was performed
using 25 l of either PBL or PBL coculture DNA lysates in
a generic, nested PCR of the integrase region by using
methods previously described (Heneine et al., 1998;
Schweizer and Neumann-Haefelin, 1995). These generic
primers, termed 1–4, have been previously shown to have a
copy number sensitivity of 1–10 genomes per 105 cells and
can detect divergent SFV sequences from both monkeys and
apes (Schweizer and Neumann-Haefelin, 1995). Nested
PCR products were electrophoresed in 1.8% agarose gels
and visualized by ethidium bromide staining. For sequence
analysis, PCR products were purified using the Qiaquick
PCR purification kit (Qiagen Inc., Valencia, CA) and
then sequenced in both directions using a Big Dye ter-
minator cycle kit (PE Biosystems, Foster City, CA) and a
373 automated sequencer (PE Biosystems). Percentage nu-
cleotide divergence was determined with the GAP pro-
gram in the Wisconsin sequence analysis package on a
UNIX workstation. Sequences were aligned using the
Clustal W program (Thompson et al., 1994), and the
alignments were imported into various programs in either
the PAUP* (beta version 5.0) or the MEGA (version
2.1) packages (Kumar et al., 2001; Rogers and Swofford,
1999).
Distance-based trees were generated by using the
Kimura two-parameter model in conjunction with the
Neighbor Joining and Minimum Evolution methods in the
MEGA program. A total of 1000 bootstrap replicates were
used to test the reliability of the final tree topology. Char-
acter-based tree-building methods were performed by using
the maximum likelihood (ML) procedures included in the
PAUP* software (Rogers and Swofford, 1999). For ML
analyses, the quartet puzzling method was used with the
following parameters: quartets evaluated using the least-
squares method with ML distances; 10,000 puzzling steps;
all sites assumed to evolve at the same rate; empirical
frequencies; transition/transversion ratio  2; HKY (Hase-
gawa–Kishino–Yano) two-parameter model for unequal
base frequencies; and molecular clock not enforced. The
GenBank accession numbers for the four new SFV integrase
sequences are AF516484–AF516487. GenBank accession
numbers for the 17 sequences used for phylogenetic com-
parison are M74895 (SFV31k), X83293 (SFVhumAGM),
X83291 (SFV3AGM), AF049077 (SFVAGM-infected human
or case 1), AF049080 (SFVBAB-infected human or case 2),
AF049084 (SFVBAB-infected human or case 3), AF049080
(SFVBAB-infected human or case 4), AF049081 (SFVBAB),
AF049079 (SFVSMM), X83292 (SFVMAC), X83290 (SFV-
2), X54482 (SFV-1a), X58484 (SFV-1b), AF049086
(SFVPYG), M54978/M38712 (HFV), X83296 (SFV-6CPZ),
and X83296 (SFV-7CPZ), where SFVSMM and SFVPYG are
from sooty mangabey monkey and pygmy chimpanzee (bo-
nobo), respectively.
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